• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for CABOMETYX issued to EXELIXIS INC

    9/21/23 4:37:02 AM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXEL alert in real time by email
    New Drug Application (NDA): 208692
    Company: EXELIXIS INC
    • Email
    • Package Labeling

    Products on NDA 208692

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    CABOMETYX CABOZANTINIB S-MALATE EQ 20MG BASE TABLET;ORAL Prescription None Yes No
    CABOMETYX CABOZANTINIB S-MALATE EQ 40MG BASE TABLET;ORAL Prescription None Yes No
    CABOMETYX CABOZANTINIB S-MALATE EQ 60MG BASE TABLET;ORAL Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 208692

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    04/25/2016 ORIG-1 Approval Type 3 - New Dosage Form PRIORITY Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/208692Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208692Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    09/20/2023 SUPPL-16 Labeling-Package Insert

    Label is not available on this site.

    07/14/2022 SUPPL-14 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208692s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/208692Orig1s014ltr.pdf
    02/13/2023 SUPPL-13 Labeling-Container/Carton Labels, Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208692Orig1s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/208692Orig1s013ltr.pdf
    09/17/2021 SUPPL-12 Efficacy-New Indication Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208692Orig1s012correctedltr.pdf
    01/22/2021 SUPPL-10 Efficacy-New Indication Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208692Orig1s010ltr.pdf
    11/05/2020 SUPPL-9 Manufacturing (CMC)-Facility Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208692Orig1s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208692Orig1s009ltr.pdf
    07/16/2020 SUPPL-8 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208692s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208692Orig1s008ltr.pdf
    01/31/2020 SUPPL-7 Labeling-Container/Carton Labels, Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208692s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208692Orig1s007ltr.pdf
    01/14/2019 SUPPL-3 Efficacy-New Indication Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/208692Orig1s003ltr.pdf
    12/19/2017 SUPPL-2 Efficacy-New Indication Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208692s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208692Orig1s002ltr.pdf
    11/16/2017 SUPPL-1 Labeling-Container/Carton Labels Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208692Orig1s001ltr.pdf

    Labels for NDA 208692

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    02/13/2023 SUPPL-13 Labeling-Container/Carton Labels Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208692Orig1s013lbl.pdf
    02/13/2023 SUPPL-13 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208692Orig1s013lbl.pdf
    07/14/2022 SUPPL-14 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208692s014lbl.pdf
    09/17/2021 SUPPL-12 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s012lbl.pdf
    01/22/2021 SUPPL-10 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208692s010lbl.pdf
    11/05/2020 SUPPL-9 Manufacturing (CMC)-Facility Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208692Orig1s009lbl.pdf
    07/16/2020 SUPPL-8 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208692s008lbl.pdf
    01/31/2020 SUPPL-7 Labeling-Container/Carton Labels Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208692s007lbl.pdf
    01/31/2020 SUPPL-7 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208692s007lbl.pdf
    01/14/2019 SUPPL-3 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf
    12/19/2017 SUPPL-2 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208692s002lbl.pdf
    04/25/2016 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf
    Get the next $EXEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXEL

    DatePrice TargetRatingAnalyst
    2/24/2025$36.00Overweight → Equal Weight
    Wells Fargo
    1/27/2025$30.00 → $40.00Equal-Weight → Overweight
    Morgan Stanley
    1/24/2025Outperform → Perform
    Oppenheimer
    12/20/2024$36.00 → $40.00Outperform → Market Perform
    BMO Capital Markets
    12/17/2024$35.00 → $39.00Buy → Neutral
    BofA Securities
    10/16/2024$30.00 → $34.00Outperform
    RBC Capital Mkts
    9/19/2024$30.00Neutral
    UBS
    4/11/2024$25.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $EXEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Eckhardt Sue Gail sold $805,140 worth of shares (18,838 units at $42.74), decreasing direct ownership by 47% to 21,380 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      6/4/25 7:57:38 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wyszomierski Jack L sold $324,683 worth of shares (7,535 units at $43.09), decreasing direct ownership by 2% to 358,882 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      6/4/25 7:57:28 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Johnson David Edward

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      6/2/25 5:22:46 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Leadership Updates

    Live Leadership Updates

    See more
    • ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

      TORONTO, Oct. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI) (OTCQB:AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the appointment of P.J. Haley, Executive Vice President, Commercial at Exelixis, Inc. (NASDAQ:EXEL), as a director of the Company, effective October 15th, 2024. Mr. Haley will be replacing Sheetal Jaitly, who is stepping down as a director after a period of dedicated service and contributions to the Company. As NetraMark focuses on advancing its technology for late phas

      10/9/24 8:30:00 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

      – Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 – – Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; 2024 R&D expense guidance of $925 million - $975 million – – Appointment of two new board members, Mary C. Beckerle, Ph.D., and Gail Eckhardt, M.D., with extensive drug development and corporate governance expertise – – Implementing corporate restructuring to focus R&D resources on clinical stage and IND-enabling activities to maximize pipeline success and operational efficiency – – Board of Directors authorized $450 million share repurchase in 2024 after successful completi

      1/7/24 4:00:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

      -- Dr. Peterson's extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios -- Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Peterson is a veteran oncology drug development leader whose experience includes senior clinical development and operational roles at Genentech, Medivation, BeiGene and CytomX. She joins Exelixis as the company accelerates development of its product pipeline and builds on the success of its global cabozantinib oncology franchise. "With a

      8/23/23 4:30:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Financials

    Live finance-specific insights

    See more
    • Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

      - Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million - - GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 - - Increasing 2025 Full Year Net Product Revenues and Total Revenues Guidance by $100 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX® d

      5/13/25 4:07:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

      – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event

      4/29/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

      - Total Revenues of $567 million for the Fourth Quarter of 2024, $2.17 billion for the Fiscal Year 2024 - - Cabozantinib Franchise Achieved $1.81 billion in U.S. Net Product Revenues for the Fiscal Year 2024, including $515 million for the Fourth Quarter of 2024 - - GAAP Diluted EPS of $0.48 for the Fourth Quarter of 2024, $1.76 for the Fiscal Year 2024 - - Non-GAAP Diluted EPS of $0.55 for the Fourth Quarter of 2024, $2.00 for the Fiscal Year 2024 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectiv

      2/11/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care